Lv13
50 积分 2025-01-30 加入
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer
9小时前
待确认
Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
22小时前
已完结
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas
1天前
已完结
Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children’s Oncology Group study
2天前
已完结
Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
2天前
已完结
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
7天前
已完结
Role of poly(ADP-ribose) formation in DNA repair
7天前
已完结
Exploiting metabolic cell death for cancer therapy
10天前
已完结
Decoding ferroptosis for cancer therapy
10天前
已完结
The landscape of regulated cell death: It’s all downhill from here
13天前
已完结
皖公网安备34019202002308
